Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Call for abstracts
Programme
Tracks
Speakers
Side events
Venue
About the venue
Rooms
Subscribe
days
hours
minutes
seconds
Hepatitis
Sessions
Wednesday, 23 November
13:20
Hepatitis C epidemiology and prevention
13:20
to
14:50
Knowledge market 3 (K3)
Stine Hoj
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Thomas Seyler
16:50
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely,
Judy Chang
Improving knowledge, protecting health
16:50
to
18:20
Networking zone 3 (N3)
Fernando Rodriguez De Fonseca
Thursday, 24 November
10:50
How can we improve global coverage of interventions to reduce drug-related harms?
10:50
to
12:20
Main stage
Annette Verster,
Matthew Hickman
13:20
Hepatitis C testing and treatment
13:20
to
14:50
Knowledge market 3 (K3)
Julie Bruneau,
Jason Grebely
15:00
Prevention, testing and treatment of Hepatitis C and other infections
15:00
to
16:30
Networking zone 4 (N4)
Sarah Larney
16:50
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
Margriet van Laar
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Presentations
Oral presentation
Simplified HCV management algorithm for methadone clinics: a pilot study in Ukraine
Knowledge market 3 (K3)
Kostyantyn Dumchev
Short communication
Integrating hepatitis C treatment in methadone clinic in Ukraine: perspectives of participants and providers.
Networking zone 4 (N4)
Tetiana Kiriazova
Short communication
Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nationwide 2-year cross-sectional study
Networking zone 3 (N3)
Anne Berit Bech
Oral presentation
Progress towards elimination of hepatitis C among people who inject drugs in Norway
Knowledge market 4 (K4)
Knut Boe Kielland
e-poster
Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)
Networking zone 1 (N1)
Mohammed fathi Alafifi
e-poster
An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.
Networking zone 1 (N1)
Indhu Rammohan
Wednesday, 23 November
10:50
Oral presentation
1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
2. Successful models for implementation of harm reduction programmes
10:50
to
12:20
Main stage
Monica Ciupagea
Oral presentation
3. How can we improve data and mobilise funding for harm reduction support globally?
10:50
to
12:20
Main stage
Keith Sabin
Oral presentation
4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms
10:50
to
12:20
Main stage
Judy Chang
13:20
Oral presentation
The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK
13:20
to
14:50
Knowledge market 3 (K3)
Peter Vickerman
Oral presentation
Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis
13:20
to
14:50
Knowledge market 3 (K3)
Adelina Artenie
Oral presentation
Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland
13:20
to
14:50
Knowledge market 3 (K3)
Kirsten Trayner
Oral presentation
The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study
13:20
to
14:50
Knowledge market 3 (K3)
Jack Stone
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
16:50
Short communication
Successful microelimination of HCV among patients in the Romanian prison system
16:50
to
18:20
Networking zone 3 (N3)
Adrian Abagiu
Short communication
The synthetic cannabinoids ADB-FUBINACA and THJ-2201 decrease mitochondrial activity and ATP levels during neurodifferentiation of NG108-15 cells
16:50
to
18:20
Networking zone 3 (N3)
Rui Filipe Malheiro
Short communication
In vitro toxicity of the synthetic cannabinoids THJ-2201 and ADB-FUBINACA to human astrocytes
16:50
to
18:20
Networking zone 3 (N3)
Rafaela Silva
Short communication
Virtual Opioid User: Simulating the Effects of Counterfeit Pill Prevalence with a Control Theory Model
16:50
to
18:20
Networking zone 3 (N3)
Alexander Preiss
Short communication
The Influence of the Synthetic Cannabinoids AMB-FUBINACA, ADB-FUBINACA, AB-CHMINACA and THJ-2201 on In Vitro Viability and Senescence of SH-SY5Y Cells and Primary Rat Hippocampal Neurons
16:50
to
18:20
Networking zone 3 (N3)
Rita Roque Bravo
Oral presentation
2. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study
16:50
to
18:20
Knowledge market 4 (K4)
Linda Wüsthoff
Oral presentation
Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge clusterrandomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
16:50
to
18:20
Knowledge market 4 (K4)
Havard Midgard
Short communication
Impact of the COVID-19 pandemic on drug use in the Republic of North Macedonia
16:50
to
18:20
Networking zone 3 (N3)
Sanja Prosheva
Short communication
Non-pharmacological treatment interventions in UK drug and alcohol services: an exploratory study
16:50
to
18:20
Networking zone 3 (N3)
Karen Megranahan
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Thursday, 24 November
13:20
Oral presentation
Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study
13:20
to
14:50
Knowledge market 3 (K3)
Anna Conway
Oral presentation
Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis
13:20
to
14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation
A novel hepatitis C intervention in Denmark to test and treat people who inject drugs
13:20
to
14:50
Knowledge market 3 (K3)
Jonas Demant
15:00
Short communication
Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times
15:00
to
16:30
Networking zone 4 (N4)
Josie Smith
Short communication
Harm reduction services in the Netherlands: recent developments and challenges.
15:00
to
16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Short communication
Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States
15:00
to
16:30
Networking zone 4 (N4)
Mance Buttram
Short communication
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland
15:00
to
16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication
Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort
15:00
to
16:30
Networking zone 4 (N4)
Ilhame Anwar
Short communication
Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden
15:00
to
16:30
Networking zone 4 (N4)
Martin Kåberg
Short communication
Educations for safer injection in the Mobile Drug Consumption Room in Lisbon
15:00
to
16:30
Networking zone 4 (N4)
Ângela Leite
16:50
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
18:30
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff